Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
| Revenue: $0M |
| Revenue Growth (YOY): nan% |
| Profit (% of Rev): nan% |
| Income (% of Rev): -inf% |
| Income Growth (YOY): 85778.15% |
| Operating Income: $-12638M |
| Operating Cash Flow: $-13599M |
| Operating Cash Flow Growth (YoY): 211326.52% |
| Annual Dividend Yield: 0.00% |
| Total Assets: $14.36B |
| Total Liabilities: $7.30B |
| Cash & Equivalent: $12.64B |
| Total Debt: $0M |
| Debt/Equity: 0.00 |
| Quick Ratio: 2.34 |
| Current Ratio: 2.34 |
| Price/Book: 14.81 |
| Price/Earnings: -2.07 |
| EBITDA: $-12638M |
| EPS: -0.97 |
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Sell.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.